Literature DB >> 11948065

The design of randomized clinical trials in critically ill patients.

Paul C Hébert1, Deborah J Cook, George Wells, John Marshall.   

Abstract

There are a number of difficulties in the conduct of randomized trials in the critically ill. These include difficulties in the definition of diseases and syndromes, a heterogenous population of patients undergoing a variety of therapeutic interventions, and outcomes that may not be able to discriminate between beneficial and risky therapies. Following a brief description of different randomized clinical trials (RCTs) and design philosophies, we outline the effects of different design choices in the complex critical care environment. Once the study topic has been determined to be relevant and important, then the potential investigator must establish whether efficacy or effectiveness will be the focus of the RCT. If an effectiveness design philosophy is chosen, then broad representation of study sites, liberal eligibility criteria, easily implemented intervention study protocols, and patient-centered outcomes should be chosen. The potential investigator wishing to establish efficacy will conduct the study in the centers of excellence and adopt stringent eligibility criteria, rigorous study protocols, and opt for outcomes that will be sensitive to change. In conclusion, we describe some of the major challenges and possible solutions to help a potential investigator through the myriad of difficulties in initiating an RCT in a complex environment.

Entities:  

Mesh:

Year:  2002        PMID: 11948065     DOI: 10.1378/chest.121.4.1290

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

1.  Controversial choice of a control intervention in a trial of ventilator therapy in ARDS: standard of care arguments in a randomised controlled trial.

Authors:  H Mann
Journal:  J Med Ethics       Date:  2005-09       Impact factor: 2.903

2.  Do trials that report a neutral or negative treatment effect improve the care of critically ill patients? Yes.

Authors:  Anders Perner; Simon Finfer
Journal:  Intensive Care Med       Date:  2018-06-11       Impact factor: 17.440

3.  Neuromuscular blockers and ARDS: thou shalt not breathe, move, or die!

Authors:  Balaji Yegneswaran; Raghavan Murugan
Journal:  Crit Care       Date:  2011-09-30       Impact factor: 9.097

4.  Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study.

Authors:  Susan T Crowley; Glenn M Chertow; Joseph Vitale; Theresa O'Connor; Jane Zhang; Roland M H Schein; Devasmita Choudhury; Kevin Finkel; Anitha Vijayan; Emil Paganini; Paul M Palevsky
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

Review 5.  Practice misalignments in randomized controlled trials: Identification, impact, and potential solutions.

Authors:  Katherine J Deans; Peter C Minneci; Robert L Danner; Peter Q Eichacker; Charles Natanson
Journal:  Anesth Analg       Date:  2010-08       Impact factor: 5.108

Review 6.  [Evidence-based intensive care medicine. Practice, use and significance].

Authors:  J Graf; U Janssens
Journal:  Anaesthesist       Date:  2004-03       Impact factor: 1.041

Review 7.  Research as a Standard of Care in the PICU.

Authors:  Jerry J Zimmerman; Kanwaljeet J S Anand; Kathleen L Meert; Douglas F Willson; Christopher J L Newth; Rick Harrison; Joseph A Carcillo; John Berger; Tammara L Jenkins; Carol Nicholson; J Michael Dean
Journal:  Pediatr Crit Care Med       Date:  2016-01       Impact factor: 3.624

8.  Enabling a learning healthcare system with automated computer protocols that produce replicable and personalized clinician actions.

Authors:  Alan H Morris; Brian Stagg; Michael Lanspa; James Orme; Terry P Clemmer; Lindell K Weaver; Frank Thomas; Colin K Grissom; Ellie Hirshberg; Thomas D East; Carrie Jane Wallace; Michael P Young; Dean F Sittig; Antonio Pesenti; Michela Bombino; Eduardo Beck; Katherine A Sward; Charlene Weir; Shobha S Phansalkar; Gordon R Bernard; B Taylor Thompson; Roy Brower; Jonathon D Truwit; Jay Steingrub; R Duncan Hite; Douglas F Willson; Jerry J Zimmerman; Vinay M Nadkarni; Adrienne Randolph; Martha A Q Curley; Christopher J L Newth; Jacques Lacroix; Michael S D Agus; Kang H Lee; Bennett P deBoisblanc; R Scott Evans; Dean K Sorenson; Anthony Wong; Michael V Boland; David W Grainger; Willard H Dere; Alan S Crandall; Julio C Facelli; Stanley M Huff; Peter J Haug; Ulrike Pielmeier; Stephen E Rees; Dan S Karbing; Steen Andreassen; Eddy Fan; Roberta M Goldring; Kenneth I Berger; Beno W Oppenheimer; E Wesley Ely; Ognjen Gajic; Brian Pickering; David A Schoenfeld; Irena Tocino; Russell S Gonnering; Peter J Pronovost; Lucy A Savitz; Didier Dreyfuss; Arthur S Slutsky; James D Crapo; Derek Angus; Michael R Pinsky; Brent James; Donald Berwick
Journal:  J Am Med Inform Assoc       Date:  2021-06-12       Impact factor: 4.497

9.  Non interventional drug studies in oncology: Why we need them?

Authors:  Divya Mishra; Jesal Vora
Journal:  Perspect Clin Res       Date:  2010-10

10.  Advancing care for traumatic brain injury: findings from the IMPACT studies and perspectives on future research.

Authors:  Andrew I R Maas; Gordon D Murray; Bob Roozenbeek; Hester F Lingsma; Isabella Butcher; Gillian S McHugh; James Weir; Juan Lu; Ewout W Steyerberg
Journal:  Lancet Neurol       Date:  2013-10-17       Impact factor: 44.182

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.